<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72813">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157792</url>
  </required_header>
  <id_info>
    <org_study_id>VX12-970-001</org_study_id>
    <secondary_id>2012-003126-25</secondary_id>
    <nct_id>NCT02157792</nct_id>
  </id_info>
  <brief_title>An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy</brief_title>
  <official_title>An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <brief_summary>
    <textblock>
      An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK)
      of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts A, B, C1, C2, C3: Safety parameters, including adverse event (AEs), clinical laboratory values (serum chemistry, hematology, and urinalysis), vital signs, and electrocardiogram (ECG) assessments</measure>
    <time_frame>Screening through Safety Follow-up (approximately 22 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts C1, C2, C3: Overall Response Rate (ORR) for all subjects in Part C1 (NSCLC), ORR for subjects in Part C2 (TNBC) who are basaloid subtype and BRCA1/BRCA2 germline wild-type, ORR for all subjects in Part C3 (SCLC)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Maximum tolerated dose (MTD) of VX-970 administered in combination with cisplatin and gemcitabine and in combination with gemcitabine</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetic (PK) parameter estimates of VX-970 in combination with cisplatin and gemcitabine and in combination with gemcitabine</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Maximum tolerated dose (MTD) of VX-970 in combination with cisplatin and in combination with cisplatin and etoposide</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: PK parameter estimates of VX-970 in combination with cisplatin and in combination with cisplatin and etoposide</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: PK parameter estimates of etoposide derived from plasma concentration-time data after coadministration with VX-970 and in the absence of VX-970</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts A, B: Objective tumor response (OR) as evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C2: Overall Response Rate in all subjects in Part C2</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts C1, C2, C3: Progression Free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts C1, C2, C3: Response Duration (RD)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts C1, C2, C3: Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts C1, C2, C3: Clinical benefit (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) of 6 months or greater)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts C1, C2, C3: PK parameter estimates of VX-970 including maximum concentrations (Cmax), area under the curve (AUC), apparent volume at steady state (Vss), clearance (CL) and terminal elimination half-life (t1/2)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 + 3 dose escalation of VX-970 in combination with gemcitabine as well as gemcitabine and cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 + 3 dose escalation study of VX-970 in combination with cisplatin as well as cisplatin and etoposide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-970 in combination with gemcitabine administered in subjects with advanced non-small cell lung cancer (NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-970 in combination with cisplatin in subjects with advanced triple negative breast cancer (TNBC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-970 in combination with cisplatin or carboplatin in subjects with platinum-resistant advanced small cell lung cancer (SCLC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-970</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C1</arm_group_label>
    <arm_group_label>Part C2</arm_group_label>
    <arm_group_label>C3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part C1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Part C2</arm_group_label>
    <arm_group_label>C3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>C3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease status

          -  Parts A and B: Histologically or cytologically confirmed advanced solid tumor that is
             metastatic or unresectable and for which standard curative or palliative measures do
             not exist or are no longer effective, or for whom regimens containing gemcitabine,
             cisplatin, and/or etoposide might be considered, and with measurable disease
             according to RECIST criteria

          -  Part C1:

        For Pre-screening:

          -  Advanced (metastatic or locally-advanced unresectable and not eligible for definitive
             treatment, e.g., surgery/radiotherapy), histologically confirmed non-small cell lung
             cancer (NSCLC)

          -  Available historical tumor specimen at the time of pre-screening or willing to
             provide a tumor biopsy (core) if the biopsy may be considered as part of standard
             clinical practice for the patient

          -  Received or did not tolerate standard approved targeted therapy, if appropriate for
             tumor genotype

        For Screening:

          -  Measurable disease according to RECIST criteria

             -Part C2:

          -  Advanced (locally-advanced incurable or metastatic) histologically confirmed estrogen
             receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2)
             negative breast cancer.

          -  Adequate available historical tumor specimen or willing to provide a tumor biopsy
             (core) if the biopsy may be considered as part of standard clinical practice for the
             patient

          -  Measurable disease according to RECIST criteria

             -Part C3:

          -  Advanced (locally-advanced incurable or metastatic) histologically confirmed SCLC
             that is platinum-resistant, defined as disease progression during initial treatment
             with a platinum-based regimen or progression within 90 days of completion of platinum
             therapy. Subjects with platinum-resistant disease may receive a second-line
             non-platinum-based chemotherapy and subsequently be enrolled to this study. Subjects
             who received and are resistant to a second-line platinum-based chemotherapy may also
             be enrolled into the study.

          -  Adequate available historical tumor specimen or willing to provide a tumor biopsy
             (core) if the biopsy may be considered as part of standard clinical practice for the
             patient

          -  Measurable disease according to RECIST criteria

          -  WHO performance status of 0 or 1

          -  Life expectancy of ≥12 week

          -  Hematological and biochemical indices within protocol specified ranges at screening.

        Exclusion Criteria:

          -  Radiotherapy (except for palliative reasons) endocrine therapy, immunotherapy, or
             chemotherapy during the previous 4 weeks (6 weeks for nitrosoureas and Mitomycin-C,
             and 4 weeks for investigational medicinal products) or less than 4 drug half-lives,
             whichever greater, before first dose of study drug.

          -  Parts A and B:

               -  Greater than 6 cycles of prior treatment with cisplatin and/or carboplatin.

                  (a) History of prior dose reductions or dose interruptions while receiving
                  cisplatin or carboplatin due to toxicity from the platinum or intolerance to
                  either agent.

               -  Subjects with a known history of Grade 4 thrombocytopenia or Grade 4 neutropenia
                  while receiving prior therapy.

          -  Part C1:

               -  Any cytotoxic chemotherapy beyond 1 line of platinum-based chemotherapy. One
                  additional line of non-platinum based therapy in the advanced setting

                    1. Pre-screening Only*: Subjects may currently be receiving platinum-based
                       chemotherapy in the advanced setting, or have completed 1 line of
                       platinum-based chemotherapy and are currently receiving a second-line
                       non-platinum-based therapy or maintenance therapy

                    2. There is no restriction on prior immunotherapy or targeted therapy unless
                       combined together with a cytotoxic agent

               -  Any prior gemcitabine for the treatment of NSCLC in any setting within 6 months

               -  Subjects who are known to be TP53 wild-type, unless they are determined to have
                  ATM loss of expression during screening or pre-screening or until all the
                  planned subjects with TP53 mutation are enrolled as determined by the medical
                  monitor

               -  Subjects with unknown TP53 mutational status will be enrolled until the group of
                  approximately 10 subjects without TP53 mutation or until all the planned
                  subjects with TP53 mutation are enrolled as determined by the medical monitor

          -  Part C2:

               -  Any prior platinum therapy in the adjuvant or neoadjuvant within 6 months of
                  screening

               -  Relapse within 3 months of completion of prior adjuvant or neoadjuvant
                  chemotherapy

               -  Any prior chemotherapy in the metastatic setting with the exception of either a
                  taxane or an anthracycline in the first-line metastatic setting

                  (a) There is no restriction on prior immunotherapy or targeted therapy in the
                  metastatic setting unless combined together with a cytotoxic agent

               -  Subjects with known BRCA1/BRCA2 germline mutations, either determined and
                  documented prior to Screening, or determined during Screening. Subjects with
                  unknown BRCA1/BRCA2 status may be enrolled at discretion of the sponsor

               -  Subjects who are documented to be non-basaloid subtype using molecular profiling
                  assay (e.g. PAM50 assay) prior to Screening

               -  Subjects with unknown BRCA1/BRCA2 or basaloid subtype status will be enrolled
                  until the number of enrolled subjects is approximately 40. If approximately 40
                  subjects have been enrolled and a minimum of 30 subjects who are basaloid
                  positive and BRCA1/BRCA2 germline wild-type have not been enrolled, the basaloid
                  subtype and BRCA status assay will be required at Screening to exclude subjects
                  who are basaloid negative or have BRCA1/BRCA2 germline mutations.

          -  Part C3:

               -  Prior platinum-sensitive subjects, unless they progress on or within 90 days of
                  completion of platinum-based regimen

               -  There is no restriction on prior immunotherapy or targeted therapy in the
                  metastatic setting unless combined together with a cytotoxic agent

               -  During prior carboplatin therapy, requirement for dose reduction below AUC 5
                  mg.min/mL or discontinuation of carboplatin for toxicity or lack of
                  tolerability.

          -  Unresolved toxicity of Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
             or greater from previous anti-cancer therapy or radiotherapy

          -  History of spinal cord compression or brain metastases, unless asymptomatic, treated,
             stable, and not requiring treatment with steroids for at least 4 weeks before first
             dose of study drug. Any history of leptomeningeal metastases.

          -  Female subjects who are already pregnant or lactating, or plan to become pregnant
             within 6 months of the last dose of study drug are excluded. Female subjects of
             childbearing potential must adhere to contraception guidelines

          -  Male subjects with partners of child-bearing potential must agree to adhere to
             contraception guidelines. Men with pregnant or lactating partners or partners who
             plan to become pregnant during the study or within 6 months of the last dose of study
             drug are excluded

          -  Serious cardiac or other co-morbid disease, as specified in the protocol

          -  Prior bone marrow transplant or extensive radiotherapy to greater than 15% of bone
             marrow

          -  Part C:

               -  Current malignancies of other types, with the exception of adequately treated
                  cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell
                  carcinoma of the skin

          -  Major surgery ≤2 weeks before starting study drug, or incomplete recovery from a
             prior major surgical procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>November 15, 2016</lastchanged_date>
  <firstreceived_date>June 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
